A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Filgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Adverse reactions; Therapeutic Use
- Acronyms REaCT-G2
- 20 Apr 2020 Results (n=466) from NCT02428114 and NCT02816164, evaluating whether 5 days of Filgrastim is non inferior tp 7/10 days for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer, published in the Annals of Oncology
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.
- 01 Mar 2019 Status changed from recruiting to active, no longer recruiting.